Shaperon(http://www.shaperon.com/eng/main/) is a clinical stage biotech company developing novel inflammasome inhibitors and was listed in KOSAQ(378800) in 2022. I work for licensing developing medicines.

Started Bio Venture business

Head of Business Development in Bukwang Pharmaceuticals together with CNS marketing

Marketing• Launched ENSTILUM®(psoriasis medicine) and differentiated it from existing portfolios, reaching 20% of market share at 1st year of launch and preparing for launch of ADTRAZA®(atopic dermatitis biologics) in line with global brand strategy applying local market environment• Create and execute key stakeholder management plan and roadmaps for new biologics setup for registration and market access • Set up brand plans that aligns and includes practical tools to implicate plans in Korea through multiple workshop/meetings with relevant staff• Raised market leadership in saturated psoriasis & atopic dermatitis market by setting new strategy to focus on clinic market by sharing real world cases• Headed project to enhance digital activities including webinars, engaged emails, and websites for seamless message delivery during COVID-19 period• Led efficiency project to raise call efficiency by Multichannel Cycle Plan to combine online and offline activities that includes practical tool to enroll and deliver digital messageBusiness Development• New business proposals reflecting unmet need based on competitive structure, as a HQ member of ‘play to win’, that eventually made new biologics license in• Implemented effective and efficient business procedures for the negotiation with Dongwha for FUCIDIN® deal and significantly increased profit with new terms• Led business transfer project of PROTOPIC®(atopic dermatitis drug) from Astellas and ran transfer of 4 dermatology products from Bayer• Open Innovation launch to boost global license in from Korea, with JW1601(Joongwae), released 80 articles, and hold a pitching contest with 8 pre-selected Korean bio venturesMarket Access• Setting pricing and reimbursement strategy of ADTRAZA® as risk sharing agreement (RSA) and completed pricing and reimbursement of new product, ENSTILUM® • Defensed massive price cut of established products given by HIRA by analyzing gap between HIRA reimbursement claim and sales

Managed 30 commercial staff (20 sales reps., 3 district sales managers, 1 key account manager, 1 sales force effectiveness manager, 2 product managers, 1 assistant product manager, 1 market access/public affairs manager, 1 digital manager)• Led segmentation and target setting for sales representatives and develop new incentive scheme and target setting system • Accelerated sales growth by setting focus bricks and follow up message delivery in target focus bricks

Marketing• Launched BRINTELLIX®(antidepressant) and completed listing in major hospitals within 6 months and AZILECT®(Parkinson’s disease drug) by doubling target sales• Increased LEXAPRO®(antidepressant) market leadership and constantly increased EBIXA®(Alzheimer’s’ disease drug) market share every year despite generic competition• Received 2015 Lundbeck Global Commercial Conference Award for best business achievement Business Development• Coordinating all partnership issues including KPI setting, sales force deployment, message delivery, management meetings, and service fee payment• Completed license in deal with Teva for AZILECT® and complete business cases and got local launch approval of AZILECT® and Brintellix• Set up license out of LEXAPRO® with Jeil for clinic business and terminated contract with Whanin after long-term partnership without any major issueMarket access• Set up market access strategies for AZILECT® and BRINTELLIX® • Led communications with stakeholders for the pricing and reimbursement of AZILECT® and BRINTELLIX®PR activity• Generated media exposure about the launch of AZILECT® • Joined London Economist forum and successfully released the results in top newspaper (Chosun Ilbo) and broadcast (MBC) about depression related to productivity

• Was responsible for pre-marketing activities of AZILECT® in Australia• Led the patient familiarization program of AZILECT® before the launch and doubled the patient target enrollment

• Executed all tasks related to marketing, market access, regulatory affairs, scientific affairs, price listing, and clinical trials

• Experienced in oncology, hematology, neurology, and dermatology field• Responsible for BETAFERON®(multiple sclerosis medicine) and established a new market as the first product and managed orphan drug business in expanding reimbursement to 100%• Responsible for digital marketing of Bayer Korea’s oral contraceptive; DIANE®, managed corporate communications and PR of Bayer Korea

• Accomplished the registration and price listing for reimbursement • Coordinated the global licensing of FACTIVE®(antibiotics, first Korean medicine approved by US FDA) to GSK